Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHXTNW)

Drug Name
LY-2228820 Drug Info
Synonyms
Ralimetinib; 862505-00-8; LY-2228820 free base; UNII-73I34XW4HD; 73I34XW4HD; 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine; C24H29FN6; Ralimetinib [USAN:INN]; LY2228820 free base; Ralimetinib (USAN/INN); GTPL7959; SCHEMBL3989306; SCHEMBL13826263; CHEMBL2364626; DTXSID00235456; MolPort-009-679-493; XPPBBJCBDOEXDN-UHFFFAOYSA-N; BCPP000180; BCP02033; ZINC34630490; ABP000309; 2526AH; ABP000548; AKOS027282678; SB16635; BCP9000871; DB11787; NCGC00346537-05; LY-2180895; LY-2211877; LY-2228820 mesylate; LY-2231377; LY-2322600; LY-479754; LY-22288202MsOH; P38 MAP kinase inhibitors (inflammation, cancer), Lilly
Cross-matching ID
PubChem CID
11539025
CAS Number
CAS 862505-00-8
TTD Drug ID
D08WYH

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Neutrophil extracellular trap formation 2.04 1.13e-2 101/189 (53.44%) TLR4;FGG;PRKCA;...
Regulation of lipolysis in adipocytes 2.03 5.63e-3 52/55 (94.55%) GNAS;PLAAT3;PRKACB;...
Insulin secretion 2.01 3.76e-3 75/86 (87.21%) GNAS;SNAP25;PRKACB;...
Long-term depression 2.01 2.82e-3 55/60 (91.67%) GNAS;GRIA2;GUCY1A1;...
Circadian entrainment 1.95 4.51e-3 85/97 (87.63%) GNAS;GRIA2;GUCY1A1;...
Carbohydrate digestion and absorption 1.89 7.51e-3 37/47 (78.72%) SLC37A4;PLCB4;FXYD2;...
Glutamatergic synapse 1.89 6.44e-3 97/114 (85.09%) GNAS;SLC38A1;GRIA2;...
Pentose phosphate pathway 1.80 1.41e-2 25/30 (83.33%) TKT;G6PD;PGD;...
Aldosterone-regulated sodium reabsorption 1.79 1.38e-2 34/37 (91.89%) IGF1;PRKCA;SGK1;...
Cortisol synthesis and secretion 1.78 1.24e-2 58/65 (89.23%) GNAS;PRKACB;PLCB4;...
Intestinal immune network for IgA production 1.76 1.33e-2 38/48 (79.17%) CXCL12;ITGB7;ITGA4;...
Renin-angiotensin system 1.76 1.22e-2 20/23 (86.96%) CTSA;ANPEP;ACE2;...
Taste transduction 1.75 1.30e-2 61/86 (70.93%) PRKACB;GABBR1;PLCB4;...
Fc gamma R-mediated phagocytosis 1.71 2.66e-2 79/97 (81.44%) PAK1;CRK;PRKCA;...
Asthma 1.71 2.55e-2 25/31 (80.65%) FCER1A;HLA-DPA1;HLA-DQB1;...
Dopaminergic synapse 1.70 2.96e-2 115/132 (87.12%) GNAS;GRIA2;PRKACB;...
Drug metabolism 1.69 3.18e-2 78/151 (51.66%) CES1;ADH1B;DPYD;...
Renin secretion 1.68 3.25e-2 61/69 (88.41%) GNAS;GUCY1A1;PRKACB;...
Endocrine and other factor-regulated calcium reabsorpti... 1.68 3.08e-2 49/53 (92.45%) GNAS;PRKACB;PRKCA;...
Morphine addiction 1.65 4.00e-2 80/91 (87.91%) GNAS;PRKACB;GABBR1;...
Salivary secretion 1.64 4.24e-2 76/93 (81.72%) GNAS;GUCY1A1;PRKACB;...
Base excision repair 1.63 4.20e-2 29/33 (87.88%) HMGB1;PARP2;POLD2;...
Cholinergic synapse 1.63 4.16e-2 99/113 (87.61%) PRKACB;PRKCA;CAMK2G;...
Aldosterone synthesis and secretion 1.62 4.41e-2 85/98 (86.73%) GNAS;PRKACB;PRKCA;...
Growth hormone synthesis, secretion and action 1.61 4.46e-2 108/119 (90.76%) GNAS;PRKACB;IGF1;...
GABAergic synapse 1.60 4.59e-2 76/89 (85.39%) SLC38A1;PRKACB;GABBR1;...
Inositol phosphate metabolism 1.60 4.51e-2 66/73 (90.41%) PLCB4;INPP4A;PIK3C2B;...
Platelet activation 1.60 4.47e-2 106/124 (85.48%) GNAS;GUCY1A1;PRKACB;...
Steroid biosynthesis 1.59 4.58e-2 19/20 (95%) LSS;DHCR24;SQLE;...
Ascorbate and aldarate metabolism 1.59 4.77e-2 15/30 (50%) RGN;GUSB;UGT2B28;...
TGF-beta signaling pathway -1.72 3.22e-2 81/94 (86.17%) SMAD4;ID4;TGFBR1;...
Huntington disease -1.75 2.26e-2 233/306 (76.14%) CREB3;PIK3C3;CYC1;...
Nitrogen metabolism -1.75 2.49e-2 16/17 (94.12%) GLUL;CA6;CA14;...
Parkinson disease -1.78 2.10e-2 176/249 (70.68%) CYC1;PSMC4;MAPT;...
Proteasome -1.79 2.04e-2 44/46 (95.65%) PSMC4;PSMA7;PSMB2;...
Oxidative phosphorylation -1.80 1.96e-2 93/133 (69.92%) NDUFB8;ATP6V1C1;NDUFA4;...
Bladder cancer -1.83 1.57e-2 40/41 (97.56%) MAPK1;SRC;CCND1;...
IL-17 signaling pathway -1.84 1.37e-2 84/94 (89.36%) MAPK13;FOS;IL17B;...
Prion disease -1.88 1.07e-2 209/273 (76.56%) MAPK13;CREB3;CYC1;...
Amyotrophic lateral sclerosis -1.92 1.43e-2 267/364 (73.35%) NDUFB8;DCTN5;BECN1;...
TNF signaling pathway -2.03 4.29e-3 103/112 (91.96%) TRAF1;IL18R1;IFNB1;...
Mineral absorption -2.27 0.00e+0 48/60 (80%) TF;FTH1;MT1F;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H